Endometrial Cancer Clinical Trial
Official title:
Radiomics Based on Multimodal Transvaginal Ultrasound Imaging in Predicting Endometrial Cancer and Cervical Stromal Invasion
Verified date | May 2022 |
Source | Tongji Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Retrospectively collect preoperative transvaginal B-mode ultrasound (BMUS), color Doppler flow imaging (CDFI) and three-dimensional ultrasound (3D-US) images and clinical data in patients with non-endometrial cancer diseases and endometrial cancer confirmed by pathology. They were grouped as training set(Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology) and external validation set(Women's Hospital, School of Medicine, Zhejiang University) . Radiomics features were extracted from corresponding transvaginal ultrasound images. Then, the minimum redundancy maximum relevance (mRMR) algorithm and the least absolute shrinkage and selection operator (LASSO) regression were used to select the non- malignant or malignant status-related features and cervical stromal invasion (CSI) status or non-CSI status features and construct the transvaginal ultrasound radiomics score (Rad-score). Multivariate logistic regression was performed using the three radiomics score together with clinical data, and subsequently develop a nomogram to diagnosis endometrial cancer and CSI respectively. The performance of the nomogram was assessed by discrimination, calibration, and clinical usefulness in the training and external validation set.
Status | Active, not recruiting |
Enrollment | 2000 |
Est. completion date | July 1, 2023 |
Est. primary completion date | December 1, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients diagnosed by operation and pathology 2. Patients with preoperative transvaginal ultrasound images Exclusion Criteria: 1. Past history of gynecological malignant tumors 2. Previous pelvic surgery or radiotherapy or chemotherapy 3. Poor image quality 4. Incomplete pathological or diagnosis report |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Tongji Hospital | Women's Hospital School Of Medicine Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC value | Area under the receiver operating characteristic (ROC) curve (AUC) | through study completion, an average of 1 year | |
Secondary | Diagnostic specificity | diagnosis specificity of intelligent ultrasound analysis | through study completion, an average of 1 year | |
Secondary | Diagnostic sensitivity | diagnosis sensitivity of intelligent ultrasound analysis | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02413606 -
ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?
|
N/A |